Nutriband Inc. (NTRB) Stock

Nutriband Inc. specializes in the development of a diverse portfolio of transdermal pharmaceutical products aimed at addressing various medical needs. At the forefront of their innovation is AVERSA fentanyl, a transdermal system designed to provide extended-release fentanyl while incorporating abuse-deterrent technology. This product caters specifically to patients and clinicians managing chronic pain requiring continuous opioid therapy. Nutriband Inc. also focuses on advancing other transdermal therapies such as AVERSA buprenorphine, AVERSA methylphenidate for attention deficit hyperactivity disorder (ADHD), exenatide for type 2 diabetes management, and follicle stimulating hormone for infertility treatment.

In addition to its robust pipeline of transdermal products, Nutriband Inc. has entered into a strategic license agreement with Rambam Med-Tech Ltd. This partnership aims to develop the RAMBAM Closed System Transfer Devices, further expanding Nutriband Inc.'s capabilities in delivering advanced medical technologies. Founded in 2016 and headquartered in Orlando, Florida, the company continues to innovate at the intersection of pharmaceuticals and transdermal delivery systems, positioning itself as a key player in the healthcare industry.

Nutriband Inc. was established with a mission to revolutionize healthcare through its cutting-edge transdermal pharmaceutical offerings. Since its inception, the company has focused on developing innovative solutions like AVERSA fentanyl, which offers both extended-release benefits and abuse-deterrent features for enhanced patient safety and comfort. Beyond pain management, Nutriband Inc. is committed to expanding its product portfolio to include treatments for ADHD, diabetes, and infertility. Through strategic partnerships like the one with Rambam Med-Tech Ltd., Nutriband Inc. aims to continually advance its technology and contribute to improving patient outcomes globally. Headquartered in Orlando, Florida, Nutriband Inc. remains dedicated to pioneering new frontiers in transdermal drug delivery and pharmaceutical innovation.